Latest Content

PBM legislation is rising nationwide, which experts emphasize could increase costs and hinder patient care.

Guideline adherence in treating acute lymphoblastic leukemia (ALL) enhances health care resource utilization, especially for adolescent and young adult patients.

Changing the FDA biosimilar interchangeability standards is a necessary but likely insufficient step to improve biosimilar competition in the US.

Though patients with type 2 diabetes or chronic kidney disease (CKD) face a greater risk of heart failure (HF) following acute myocardial infarction (AMI), patients without those comorbidities also benefit from empagliflozin.

Deuruxolitinib 8 mg BID was found to be the most effective oral JAK inhibitor for severe alopecia areata in a new meta-analysis.

Despite clinical definitions suggesting patients recover from exacerbations within 2 weeks of hospital discharge, most patients in a qualitative survey believed they had not achieved recovery within 3 months.

Combining ELR with CT-based measures predicts olfactory recovery in CRSwNP patients, highlighting eosinophils' role in disease severity and dysfunction.

Geni Tunstall, JD, discusses how pharmacy benefit manager reforms, Medicaid changes, and the MAHA initiative may impact managed care pharmacy operations.

Experts at AMCP Nexus 2025 highlighted how real-world data can improve CAR T-cell therapy access and outcomes.